Loading color scheme

News

Virtici, Celdara Medical, and MBV Announce Collaboration

Today Virtici, Celdara Medical and MBV announced their formation of the first collaborative nationwide network for the development of early stage biotechnologies. The goals are simple: to improve human health by identifying the highest potential innovations in medicine and developing them into the clinic.

Read more

Cardio3 Biosciences Acquires OnCyte CAR T-Cell Portfolio from Celdara Medical

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, today announced the acquisition of OnCyte, LLC a division of Celdara Medical, and its portfolio of immuno-oncology CAR T cell product candidates.

Read more

Virtici Launches Collaboration to Identify and Progress High Potential Preclinical Therapeutics

Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly investigate novel therapeutic candidates and thereby further strengthen the Daiichi Sankyo developmental pipeline across multiple therapeutic areas.

Read more